> ## Content Index
> Fetch the complete content index at: https://morpheus-research-labs.ghost.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# KPV Tripeptide Research: The Alpha-MSH Fragment in the Literature
- URL: https://morpheus-research-labs.ghost.io/kpv-peptide-research/
- Published: 2026-10-30T21:17:06.000Z
- Updated: 2026-10-30T21:17:06.000Z
- Description: KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH. What published research, including a 2008 mouse study, reported on inflammation signalling.
- Author: Morpheus Research
- Tags: Research

KPV is a three-amino-acid peptide, lysine-proline-valine, that has attracted research interest out of proportion to its size. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), a hormone known for its role in pigmentation and, in research, for its anti-inflammatory signalling. KPV has been studied as a way to investigate those signalling properties in a much smaller molecule. This article covers its origins, the key published research and practical considerations for labs.

![Overview of this guide](https://storage.ghost.io/c/fb/21/fb21afd5-6993-4fea-b3b8-8aef28c1314f/content/images/2026/10/key-sections-10.png)

## Origins in α-MSH research

α-MSH is a 13-amino-acid peptide derived from the precursor protein pro-opiomelanocortin (POMC). It acts on melanocortin receptors, notably MC1R in pigment cells. Beyond pigmentation, research since the 1980s has reported that α-MSH influences inflammatory signalling in a range of cell and animal models.

Researchers investigating which part of α-MSH was responsible for these effects found that its final three residues, Lys-Pro-Val, retained notable anti-inflammatory activity in some experimental models. Interestingly, this tripeptide appears to act at least partly through mechanisms that do not depend on the melanocortin receptors that mediate pigmentation, which makes it a useful tool for separating those functions.

## Key published research

### Intestinal inflammation models

The most cited KPV study is by Dalmasso and colleagues, published in *Gastroenterology* in 2008: "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." The authors reported that KPV was taken up by intestinal epithelial cells through PepT1, a transporter for di- and tripeptides that is expressed in the gut and induced during inflammation. In cultured intestinal cells, KPV was associated with reduced activation of the inflammatory signalling pathways NF-κB and MAPK and reduced secretion of inflammatory cytokines. In mouse models of chemically induced colitis, KPV administration was associated with reduced measures of inflammation.

This study is notable for identifying a specific uptake mechanism: because PepT1 transports small peptides, the tripeptide can enter cells directly, where it was reported to act on intracellular signalling.

### Later work

Subsequent research has explored KPV in delivery systems, such as nanoparticle formulations studied in mouse colitis models, and in other inflammation-related cell and animal models. These remain preclinical investigations.

## Limits of the evidence

- The research base is relatively small.
- Most findings come from cell culture and mouse models.
- Controlled human clinical evidence is lacking.
- Mechanisms are not fully resolved, and may differ between cell types.

KPV is a research tool for studying inflammatory signalling and peptide transport. It should not be described as a treatment for any condition.

![Key points for labs](https://storage.ghost.io/c/fb/21/fb21afd5-6993-4fea-b3b8-8aef28c1314f/content/images/2026/10/key-points-10.png)

## Research applications

- Inflammatory signalling studies (NF-κB, MAPK pathways) in cell culture.
- Peptide transporter research, particularly PepT1.
- Comparisons with full-length α-MSH and other melanocortin peptides.
- Drug-delivery and formulation research.

## Characterization and handling

At about 342 daltons, KPV is small and straightforward to characterize. A certificate should show HPLC purity and mass spectrometry identity. Very small peptides can be hygroscopic, so moisture control matters:

- Store lyophilized KPV cold, dry and protected from light.
- Equilibrate vials before opening.
- Reconstitute with a suitable sterile diluent such as [bacteriostatic water](https://morpheusresearch.cloud/product/bac-water/?ref=morpheus-research-labs.ghost.io) or an assay-compatible buffer.
- Refrigerate solutions and avoid repeated freeze-thaw cycles.

## Sourcing

Morpheus Research supplies [KPV 10mg](https://morpheusresearch.cloud/product/kpv-10mg/?ref=morpheus-research-labs.ghost.io) for laboratory research. Ask for the batch certificate, and use the [contact page](https://morpheusresearch.cloud/contact/?ref=morpheus-research-labs.ghost.io) for volume pricing.

## KPV compared with full-length alpha-MSH

Researchers often study KPV alongside full-length α-MSH to separate their functions. α-MSH acts on several melanocortin receptors, which complicates interpretation in cell types that express more than one. KPV's small size, its reported PepT1-mediated uptake and its apparent independence from the pigmentation receptor make it useful for asking which effects require receptor binding and which may involve intracellular action. Well-designed comparisons include both peptides at matched molar concentrations, vehicle controls and, where possible, cells with and without PepT1 expression, so that the transport question can be tested directly rather than assumed.

## Peptide transport research

KPV's reported uptake through PepT1 links it to a broader research field. PepT1 (SLC15A1) is a proton-coupled transporter that moves di- and tripeptides across the intestinal lining, and it is also studied because it carries some drugs, such as certain antibiotics and prodrugs. Its expression in the colon is normally low but has been reported to increase in inflamed tissue in some studies.

Researchers use KPV and similar small peptides to study:

- **Transport kinetics**, by measuring uptake at different concentrations.
- **Competition**, by adding other di- or tripeptides to see whether they reduce uptake.
- **Transporter dependence**, using cells engineered to express or lack PepT1, or using known inhibitors.

These experiments help establish whether a biological effect requires the peptide to enter cells.

## Study design considerations

- **Stability.** Very short peptides can be degraded by peptidases in serum-containing media. Short time-course experiments establish how long KPV remains intact.
- **Scrambled controls.** Peptides with the same amino acids in a different order, such as VPK, help show whether effects are sequence-specific.
- **Inflammatory stimulus.** Cell studies usually trigger inflammatory signalling with a defined stimulus, such as a cytokine or bacterial product. The choice and concentration of stimulus affects results and should be reported.
- **Readouts.** NF-κB activation, MAPK phosphorylation and cytokine secretion are common measures. Pick primary outcomes in advance.

## Reading the KPV literature

The 2008 Gastroenterology study combined several approaches: uptake experiments in intestinal epithelial cell lines, competition experiments using unlabelled KPV against PepT1-mediated transport, signalling assays and two chemically induced mouse colitis models, DSS and TNBS, with KPV given in drinking water. That combination of mechanism and in vivo models is part of why the paper is widely cited. When reading later work, check whether it used the same models, how KPV was delivered, and whether PepT1 dependence was tested directly or assumed. Small differences in these choices make results hard to compare across papers.

Researchers should also note that most published KPV work concerns the intestine, where PepT1 is abundant. Findings in other tissues, where the transporter may be absent or expressed at low levels, should not be assumed to follow the same pattern without direct testing. Likewise, effects reported at nanomolar concentrations in cell lines should be compared carefully with the concentrations used in other studies, since dose-response relationships for small peptides can be steep and model-dependent.

## Frequently asked questions

**What is KPV?** The tripeptide lysine-proline-valine, the C-terminal fragment of alpha-MSH.

**How does KPV enter cells?** Research reports uptake through the peptide transporter PepT1 in intestinal epithelial cells.

**What did the research report?** Cell and mouse studies reported reduced inflammatory signalling and reduced measures of colitis in models.

**Is KPV approved for any use?** No. It is sold as a research compound only.

**Does KPV affect pigmentation like α-MSH?** Research suggests its anti-inflammatory activity is at least partly independent of the melanocortin receptor that mediates pigmentation.

## Related reading

- [Peptide COA Explained: How to Read a Certificate of Analysis](https://morpheus-research-labs.ghost.io/peptide-coa-explained/)
- [How to Store Research Peptides: Lyophilized and Reconstituted Handling](https://morpheus-research-labs.ghost.io/how-to-store-research-peptides/)
- [Peptide Reconstitution with Bacteriostatic Water: A Lab Handling Guide](https://morpheus-research-labs.ghost.io/peptide-reconstitution-bacteriostatic-water/)
- [Glutathione in Oxidative Stress Research: A Lab-Focused Overview](https://morpheus-research-labs.ghost.io/glutathione-oxidative-stress-research/)
- [Longevity Peptide Research: Mapping Compounds to the Hallmarks of Ageing](https://morpheus-research-labs.ghost.io/longevity-peptides-research/)

## References

- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. *Gastroenterology.* 2008;134(1):166-178\. PMID: 18061177.

---

*Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.*

**For research use only. Not for human consumption.**